Using GLP-1RAs instead of insulin cost US$54,851 and US$29,115 per case of all-cause mortality and hospitalized hypoglycemia prevented, respectively, from the payer perspective, and saved US$19,391 and US$10,293, respectively, from the healthcare sector perspective
Whereas, over-the-counter pills and stimulants present too many toxicities and are highly discouraged among the medical community
For more information regarding our Privacy Policy, please review it here
(Cham: Springer International Publishing), 365376
The outcome pointed to an intriguing pattern